相关实验视频

Updated: Jan 8, 2026

Assays for Validating Histone Acetyltransferase Inhibitors

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

新型组织素脱乙酶抑制剂CS014在体内减轻血栓形成,同时保持血静

Livia Stanger¹, Pooja Yalavarthi¹, Reheman Adili¹

¹Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.

Journal of thrombosis and haemostasis : JTH

|December 13, 2025

概括

一种新药物CS014显示出作为一种抗血栓剂的承诺,它通过抑制基因组脱乙酶 (HDAC) 而不会导致肝损伤. 这种HDAC抑制剂有效地防止了受伤后的血块形成,并提供了对酸 (VPA) 更安全的替代品.

科学领域:

药理学药理学是指药理学的学科.
生物化学生物化学
血液学血液学血液学

背景情况:

价酸 (VPA) 是一种基因素脱乙酶 (HDAC) 抑制剂,用于治疗各种疾病,但具有肝毒性风险.
通过改变组织等离子体激活剂和等离子体激活剂抑制剂-1,VPA会影响血栓形成,分离和稳定性.
需要更安全的具有抗血栓潜力的HDAC抑制剂是显而易见的.

研究的目的:

开发和评估CS014,一种新型HDAC抑制剂,旨在保持HDAC抑制,同时降低肝毒性.
与VPA相比,评估CS014作为抗血栓剂的疗效.

主要方法:

CS014和VPA在体外和体内都进行了对HDAC抑制和代谢物产生的测试.
在实体中,用CS014或VPA治疗的小鼠中测量了凝块形成和出血时间.
对这两种化合物进行了ex vivo血小板活性评估.

主要成果:

CS014在没有产生肝毒代谢物的情况下,对VPA表现出可比的HDAC抑制.
CS014有效地防止了血管损伤后的血栓形成.
虽然减少了血小板和纤维素积累,但CS014并没有影响凝血或增加出血.

结论:

CS014是一种新型HDAC抑制剂,具有降低肝毒性的潜力.
CS014可能通过防止受伤引起的凝血而不会引起过度出血,提供更安全的抗血栓策略.

关键词:

在HDAC的基础上,HDAC是血液静止血液静止血静止血小板血小板血小板是什么?血栓形成的原因是血栓形成.

更多相关视频

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

相关概念视频

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Regulation of Hematopoietic Stem Cells

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...